Patricia Inácio, PhD, science writer —

Enrollment in aTyr Pharma’s pivotal Phase 3 EFZO-FIT clinical trial, testing the effectiveness and safety of efzofitimod in people with pulmonary sarcoidosis, is now complete. The study exceeded its target number of participants, recruiting 268 patients in 85 centers across the U.S., Europe, Japan, and Brazil. Top-line data are expected…

Microblading, a cosmetic technique that employs fine needles to deposit pigment to mimic the appearance of hairs, may be among triggers for sarcoidosis, according to a study. “When esthetic procedures become increasingly popular, patients with chronic lesions at the injection site of the foreign material, especially macular, papular, or…

A 37-year-old woman in Japan developed a granuloma — the clumps of cells that characterize sarcoidosis — in her thyroid gland that spontaneously regressed without steroid treatment, a case study reports. The woman also showed lesions in the skin and salivary gland, suggesting “thyroid sarcoidosis should be considered in…

The Foundation for Sarcoidosis Research (FSR) has launched the Coalition for Clinical Trial Equity, aimed at increasing the representation of Black and African American sarcoidosis patients in trials testing potential treatments. Despite Black Americans being 2.5 times more likely to have sarcoidosis than white Americans, these patients…

The Phase 2 clinical trial RESOLVE-Lung, which is testing namilumab as a treatment for people with chronic pulmonary sarcoidosis, is now fully enrolled. According to Kinevant Sciences, the therapy’s developer, 107 patients with hard-to-treat pulmonary sarcoidosis — disease that’s “not well-controlled despite currently available treatment” — have been…

A first patient has been dosed in Scotland as part of Molecure’s Phase 2 clinical trial — taking place in the U.S. and Europe — that will test the pulmonary sarcoidosis treatment candidate OATD-01 versus a placebo. “The first administration to a patient with pulmonary sarcoidosis is the realization…

Elevated blood levels of total blood cholesterol and low levels of high density lipoprotein cholesterol (HDL) — commonly called the “good” cholesterol — showed a significant correlation with sarcoidosis, according to a retrospective study conducted in China. These findings suggest HDL and total blood cholesterol “could be regarded as…

A noninvasive heart imaging scan may help identify cardiac sarcoidosis patients at risk of worse clinical outcomes, according to a study. A value of 42% or lower in left ventricular ejection fraction, or LVEF, a measure of how much blood is being pumped out of the heart’s left ventricle…

In Finland, only 2% of sarcoidosis patients without symptoms of eye involvement indeed had ocular sarcoidosis, suggesting that routine eye examinations are not needed in the Finnish patient population. But as the frequency of ocular sarcoidosis varies considerably among people with sarcoidosis worldwide, “more studies are needed to…

About six months with Acthar Gel were associated with greater therapeutic benefits than a placebo in people with pulmonary sarcoidosis receiving standard-of-care therapies, including glucocorticoids, data from a Phase 4 trial show. The benefits were sustained in those who continued treatment in an extension phase and became evident…